ReviewNPJ precision oncology2025
The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies.
Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Article
- Spatial co-expression and cell-cell communication inference from spatially resolved transcriptomics with CONCISE.bioRxiv : the preprint server for biology · 2026Article
- Article
- Targeted plasma proteomics reveals a central role of upregulated TNFRSF proteins in HIV-associated stroke.Nature communications · 2026Article
- A multimodal ocular aging index reveals proteomic pathways and predicts incident age-related eye diseases.npj aging · 2026Article
- Müller glia-microglia cross talk reprograms the Müller glia transcriptome for cell division-related processes during retina regeneration.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- STDrug enables spatially informed personalized drug repurposing from spatial transcriptomics.bioRxiv : the preprint server for biology · 2026Article
- Network pharmacology-based therapeutic intervention of Mentha arvensis targeting cancer and doxorubicin-induced cardiotoxicity.Investigational new drugs · 2026Article
- Differential Plasma Expression of sTNF-R, TNF-α, PDGF-AA, IL-17A, and IL-1β Across the Colorectal Neoplasia Spectrum.Biomolecules · 2026Article
- A single-nucleus multiome analysis of transcriptome and chromatin accessibility reveals cell-type-specific immune modulation for chronic cannabis use among people with HIV infection.bioRxiv : the preprint server for biology · 2026Article
- Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.Cancers · 2026Article
- Chronic kidney disease onset, progression, and cardiovascular outcomes: proteomics informs biology and risk stratification.Cardiovascular diabetology · 2026Article
- Pharmacologic Modulation of the PAR-2-ERK Axis by Statins Converts Inflammatory Survival Signalling into Apoptosis in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Article
- Article
- Integrative multi-cohort analysis of DNA methylation profiles for pancreatic ductal adenocarcinoma biomarker discovery and prognosis.Frontiers in bioinformatics · 2026Article
- The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.British journal of pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TNF receptor superfamily (TNFRSF) with extracellular cysteine-rich domains, transmembrane segments, and intracellular signaling motifs, plays crucial roles in cell death, inflammation, growth, and development. These cysteine-rich domains, which are located in the external portion of the TNFRSF, can contain varying numbers of domains, from as few as 1 (as seen in BCMA) to more than 3 (as observed in CD30, DR3), and function as the primary interaction sites for their corresponding ligands from TNFSF. In cancer research, TNFRSF members show abnormal expression across various cancer types, making them potential therapeutic targets. This review focuses on TNFRSF's structure, biological functions, and significance in cancer. It explores immunotherapeutic applications, targeted drug therapies, and biomarker potential, aiming to offer new perspectives on cancer diagnostics and treatments. However, challenges remain in translating these findings into effective therapies, and further research is needed to overcome these hurdles and improve cancer prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.